Selective GPR43 Agonists for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory pharmaceuticals for treating inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, often provide inadequate relief and are associated with adverse effects, highlighting a need for new therapeutic approaches that effectively target inflammatory cytokines like TNF-α and IL-8.
Innovation Solution
Development of selective GPR43 agonists or partial agonists, which are compounds that activate the G-Protein-Coupled Receptor 43, to regulate inflammatory responses by reducing TNF-α and IL-8 levels, thereby addressing the root causes of inflammation in various inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-inflammatory pharmaceuticals are used to treat inflammatory diseases, then inflammatory symptoms are suppressed, but adverse effects occur and relief is inadequate
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (Formula I) that selectively target GPR43 receptors. By modifying chemical parameters such as substituent groups (R1-R6, Ar1, Ar2) and molecular properties, the invention achieves selective agonist activity that reduces TNF-α and IL-8 production without the broad-spectrum immunosuppression caused by conventional anti-inflammatory drugs, thereby maintaining efficacy while reducing adverse effects
Solution Approach 2:
The patent introduces GPR43 agonists as intermediary compounds that mediate the anti-inflammatory effect through a specific biological pathway. These compounds act as intermediaries between the administered drug and the inflammatory cytokine cascade, selectively binding to GPR43 receptors on immune cells to modulate TNF-α and IL-8 production. This intermediary mechanism provides more precise control over the anti-inflammatory response compared to conventional drugs that directly suppress multiple immune pathways
2Adaptability or versatility
If selective GPR43 agonists are developed to target inflammatory cytokines, then specificity of action is improved, but complexity of compound structure increases
Solution Approach 1:
The patent systematically varies molecular parameters within Formula I to optimize the balance between specificity and complexity. By controlling the complexity of substituent groups (using simple alkyl, halo, cyano groups) and maintaining a defined core structure, the invention achieves selective GPR43 binding without requiring excessively complex molecular architectures. The parameter optimization ensures that compounds remain synthetically accessible while achieving the desired specificity
Solution Approach 2:
The patent applies local quality by concentrating structural complexity only in specific regions of the molecule that are critical for GPR43 binding, while keeping other regions simple. The core structure and key substituent positions (particularly Ar1 and Ar2 groups) are designed with specific properties to ensure receptor selectivity, whereas other parts of the molecule maintain simplicity to facilitate synthesis and reduce overall molecular complexity
Data Source
Figure 1~2
Figure 3A~3B
Figure 4~5
AI summary
The present invention is directed to compounds of formula (I), useful in treating and/or preventing inflammatory diseases.